Dra. Laura Fleider - IGBA

More documents

Recommendations

Info

PASADO - PRESENTE y FUTURO
AGAINST WHICH HUMAN PAPILLOMAVIRUS TYPES SHALL WE VACCINATEAND SCREEN? THE INTERNATIONAL PERSPECTIVENubia MUÑOZ 1 *, F. Xavier BOSCH 2 , Xavier CASTELLSAGUÉ 2 , Mireia DÍAZ 2 , Silvia DE SANJOSE 2 , Doudja HAMMOUDA 3 ,Keerti V. SHAH 4 and Chris J.L.M. MEIJER 51International Agency for Research on Cancer, Lyon, France2Institut Catala` d’Oncologia, Epidemiology and Cancer Registration Unit, L’Hospitalet de Llobregat, Barcelona, Spain3Registre des Tumeurs d’Alger, Institut National de Sante´ Publique, De´partement Controˆle des Maladies, Alger, Algeria4Department of Molecular Microbiology and Immunology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA5Department of Pathology, Vrije Universiteit Medical Center, Amsterdam, the NetherlandsInt. J. Cancer: 111, 278–285 (2004)
Page 1 and 2: Dra. Laura Fleider
Page 4: PAPILOMA VIRUS HUMANO (HPV) Virus d
Page 10: HPVTypesClifford Br J Cancer 2003;8
Page 13 and 14: PREVALENCIA MUNDIAL DE TIPOS DE HPV
Page 16 and 17: PREVALENCIA ESPECÍFICA POR GRUPOS
Page 18: La prevención primaria sería la s
Page 21: Detección de lesiones intraepiteli
Page 27: Porcentaje de seroconversión compa
Page 30 and 31: Tipo Mujeres Hombres6/11 >90% de l

Dra. Laura Fleider - IGBA

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?